Search

Your search keyword '"Schaeverbeke, Thierry"' showing total 476 results
Start Over Author "Schaeverbeke, Thierry" Language english
476 results on '"Schaeverbeke, Thierry"'

1. Resolution of immune checkpoint inhibitors-induced inflammatory arthritis while maintaining active treatment with checkpoint inhibitors and after its discontinuation: An observational study

Author

Ladouceur, Alexandra, Barnetche, Thomas, Prey, Sorilla, Dutriaux, Caroline, Gerard, Émilie, Pham-Ledard, Anne, Beylot-Barry, Marie, Zysman, Maeva, Veillon, Rémi, Domblides, Charlotte, Daste, Amaury, Gross-Goupil, Marine, Sionneau, Baptiste, Lefort, Felix, Mathieu, Larroquette, Richez, Christophe, Truchetet, Marie-Elise, Schaeverbeke, Thierry, and Kostine, Marie

Published
2024
Full Text
View/download PDF

5. Can efficacy and safety data from clinical trials of rituximab in RA be extrapolated? Insights from 1984 patients from the AIR-PR Registry.

Author

Nguyen, Yann, Mariette, Xavier, Gottenberg, Jacques E, Iudici, Michele, Morel, Jacques, Vittecoq, Olivier, Constantin, Arnaud, Flipo, Rene-Marc, Schaeverbeke, Thierry, Sibilia, Jean, Ravaud, Philippe, Porcher, Raphaël, and Seror, Raphaèle

Subjects
PATIENT safety, DRUG side effects, RHEUMATOID arthritis, CLINICAL trials, AUTOANTIBODIES, RITUXIMAB, TREATMENT effectiveness, ANTIRHEUMATIC agents, LONGITUDINAL method, RESEARCH, CONFIDENCE intervals, C-reactive protein
Abstract

Objectives To investigate whether the efficacy and safety data from drug-registration trials can be extrapolated to real-life RA patients receiving RTX. Methods The 'AutoImmunity and Rituximab' (AIR-PR) registry is a French multicentre, prospective cohort of RA patients treated with RTX in a real-life setting. We compared treatment responses at 12 months and serious adverse events (AEs) between eligible and non-eligible patients, by retrieving the eligibility criteria of the three rituximab-registration trials. We determined critical eligibility criteria and modelled the benefit–risk ratio according to the number of fulfilled critical eligibility criteria. Results Among 1984 RA patients, only 9–12% fulfilled all eligibility criteria. Non-eligible patients had fewer EULAR responses at 12 months (40.3% vs 46.9%, P  = 0.044). Critical inclusion criteria included swollen joints count ≥4, tender joints count ≥4, CRP ≥15 mg/l and RF positivity. Critical exclusion criteria were age >80 years, RA-associated systemic diseases, ACR functional class IV, DMARD other than MTX and prednisone >10 mg/day. Only 20.8% fulfilled those critical eligibility criteria. During the first year, serious AEs occurred for 182 (9.2%) patients (70.3% serious infections) and patients with ≥1 critical exclusion criterion were at higher risk (hazard ratio 3.03; 95% CI 2.25–4.06; for ≥3 criteria vs 0). The incremental risk–benefit ratio decreased with the number of unmet critical inclusion criteria and of fulfilled exclusion criteria. Conclusion Few real-life RA patients were eligible for the drug-registration trials. Non-eligible patients had lower chance of response, and higher risk of serious AEs. Efficacy and safety data obtained from those trials may not be generalizable to RA patients receiving RTX in real-world clinical practice. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Towards the Lowest Efficacious Dose: Results From a Multicenter Noninferiority Randomized Open‐Label Controlled Trial Assessing Tocilizumab or Abatacept Injection Spacing in Rheumatoid Arthritis in Remission.

Author

Kedra, Joanna, Dieudé, Philippe, Giboin, Caroline, Marotte, Hubert, Salliot, Carine, Schaeverbeke, Thierry, Perdriger, Aleth, Soubrier, Martin, Morel, Jacques, Constantin, Arnaud, Dernis, Emmanuelle, Royant, Valérie, Salmon, Jean‐Hugues, Pham, Thao, Gottenberg, Jacques‐Eric, Pertuiset, Edouard, Dougados, Maxime, Devauchelle‐Pensec, Valérie, Gaudin, Philippe, and Cormier, Grégoire

Subjects
RESEARCH funding, RHEUMATOID arthritis, STATISTICAL sampling, DRUG therapy, ABATACEPT, DISEASE remission, RANDOMIZED controlled trials, ANTIRHEUMATIC agents, DESCRIPTIVE statistics, INTRAVENOUS therapy, DOSE-effect relationship in pharmacology, DRUG efficacy, RESEARCH, TOCILIZUMAB, CONFIDENCE intervals, PATIENT aftercare
Abstract

Objective: We assess the clinical and structural impact at two years of progressively spacing tocilizumab (TCZ) or abatacept (ABA) injections versus maintenance at full dose in patients with rheumatoid arthritis in sustained remission. Methods: This multicenter open‐label noninferiority (NI) randomized clinical trial included patients with established rheumatoid arthritis in sustained remission receiving ABA or TCZ at a stable dose. Patients were randomized to treatment maintenance (M) at full dose (M‐arm) or progressive injection spacing (S) driven by the Disease Activity Score in 28 joints every 3 months up to biologics discontinuation (S‐arm). The primary end point was the evolution of disease activity according to the Disease Activity Score in 44 joints during the 2‐year follow‐up analyzed per protocol with a linear mixed‐effects model, evaluated by an NI test based on the one‐sided 95% confidence interval (95% CI) of the slope difference (NI margin 0.25). Other end points were flare incidence and structural damage progression. Results: Overall, 202 of the 233 patients included were considered for per protocol analysis (90 in S‐arm and 112 in M‐arm). At the end of follow‐up, 16.2% of the patients in the S‐arm could discontinue their biologic disease‐modifying antirheumatic drug, 46.9% tapered the dose and 36.9% returned to a full dose. NI was not demonstrated for the primary outcome, with a slope difference of 0.10 (95% CI 0.10–0.31) between the two arms. NI was not demonstrated for flare incidence (difference 42.6%, 95% CI 30.0–55.1) or rate of structural damage progression at two years (difference 13.9%, 95% CI −6.7 to 34.4). Conclusion: The Towards the Lowest Efficacious Dose trial failed to demonstrate NI for the proposed ABA or TCZ tapering strategy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Evolution of monoclonal gammopathy of undetermined significance in patients treated with JAK inhibitors for rheumatic diseases: data from the MAJIK-SFR registry.

Author

Faganello, Déborah, Bertrand, Anne, Meunier, Pauline, Avouac, Jérôme, Toussirot, Eric, Coury, Fabienne, Seror, Raphaele, Mélédo, Guillaume Le, Germain, Vincent, Dellal, Azedinne, Shima, Ditmar, Hulin, Cyrille, Prati, Clément, Schaeverbeke, Thierry, Richez, Christophe, Truchetet, Marie-Elise, and Kostine, Marie

Subjects
DRUG therapy for rheumatism, RHEUMATOID arthritis diagnosis, REPORTING of diseases, PATIENT aftercare, PROTEINS, JANUS kinases, MONOCLONAL gammopathies, CONTENT mining, DESCRIPTIVE statistics, RESEARCH funding, NEUROTRANSMITTER uptake inhibitors, PHARMACODYNAMICS
Abstract

Objective Monoclonal gammopathy of undetermined significance (MGUS) is common, but there are scarce data regarding the effect of DMARDs on this premalignant condition. We aimed to evaluate the impact of JAK inhibitors (JAKis) on MGUS when initiated for an active rheumatic disease. Methods Patients with monoclonal abnormality prior to JAKi initiation for an active rheumatic disease were identified through the MAJIK-SFR Registry, a French multicentre prospective study. Clinical and biological data were collected using a standardized case report form. Results Twenty patients were identified with a mean age of 65 years and a diagnosis of RA (n  = 15), PsA (n  = 3), and axial SpA (n  = 2). The JAKi prescribed was baricitinib (n  = 9), tofacitinib (n  = 6) or upadacitinib (n  = 5), with a mean duration of 15.5 months. Seventeen patients had individualized serum monoclonal protein (IgG kappa n  = 9; IgG lambda n  = 4; IgM kappa n  = 3; IgA lambda n  = 1) ranging from 0.16 to 2.3 g/dl, and three patients did not have an initial measurable spike but they had a positive serum immunofixation. With a follow-up of 4–28 months, the serum monoclonal protein level decreased in 8 of 17 patients (47%), remained stable in 8 patients (47%) and increased in 1 patient (6%). The maximal decrease observed was an initial IgG kappa of 2.3 g/dl, decreasing to 0.2 g/dl at month 14. Conclusion This study provides reassuring and promising data on MGUS evolution in patients treated with JAKis for rheumatic diseases, which may guide the choice of treatment in patients with both conditions. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. Efficacy and safety of febuxostat in 73 gouty patients with stage 4/5 chronic kidney disease: A retrospective study of 10 centers

Author

Juge, Pierre-Antoine, Truchetet, Marie-Elise, Pillebout, Evangeline, Ottaviani, Sébastien, Vigneau, Cécile, Loustau, Clotilde, Cornec, Divi, Pascart, Tristan, Snanoudj, Renaud, Bailly, Florian, Cornec-Le Gall, Emilie, Schaeverbeke, Thierry, Saraux, Alain, Dieudé, Philippe, Flipo, René-Marc, Richette, Pascal, Lioté, Frédéric, Bardin, Thomas, Chalès, Gérard, and Ea, Hang-Korng

Published
2017
Full Text
View/download PDF

22. Stricter treat-to-target in RA does not result in less radiographic progression: a longitudinal analysis in RA BIODAM.

Author

Ramiro, Sofia, Landewé, Robert, Heijde, Désirée van der, Sepriano, Alexandre, FitzGerald, Oliver, Østergaard, Mikkel, Homik, Joanne, Elkayam, Ori, Thorne, J Carter, Larché, Maggie J, Ferraccioli, Gianfranco, Backhaus, Marina, Boire, Gilles, Combe, Bernard, Schaeverbeke, Thierry, Saraux, Alain, Dougados, Maxime, Rossini, Maurizio, Govoni, Marcello, and Sinigaglia, Luigi

Subjects
CONFIDENCE intervals, DIAGNOSTIC imaging, ANTIRHEUMATIC agents, DESCRIPTIVE statistics, RESEARCH funding, LONGITUDINAL method
Abstract

Objectives To investigate whether meticulously following a treat-to-target (T2T)-strategy in daily clinical practice will lead to less radiographic progression in patients with active RA who start (new) DMARD-therapy. Methods Patients with RA from 10 countries starting/changing conventional synthetic or biologic DMARDs because of active RA, and in whom treatment intensification according to the T2T principle was pursued, were assessed for disease activity every 3 months for 2 years (RA-BIODAM cohort). The primary outcome was the change in Sharp-van der Heijde (SvdH) score, assessed every 6 months. Per 3-month interval DAS44-T2T could be followed zero, one or two times (in a total of two visits). The relation between T2T intensity and change in SvdH-score was modelled by generalized estimating equations. Results In total, 511 patients were included [mean (s. d.) age: 56 (13) years; 76% female]. Mean 2-year SvdH progression was 2.2 (4.1) units (median: 1 unit). A stricter application of T2T in a 3-month interval did not reduce progression in the same 6-month interval [parameter estimates (for yes vs no): +0.15 units (95% CI: −0.04, 0.33) for 2 vs 0 visits; and +0.08 units (−0.06; 0.22) for 1 vs 0 visits] nor did it reduce progression in the subsequent 6-month interval. Conclusions In this daily practice cohort, following T2T principles more meticulously did not result in less radiographic progression than a somewhat more lenient attitude towards T2T. One possible interpretation of these results is that the intention to apply T2T already suffices and that a more stringent approach does not further improve outcome. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

26. Biologic targeted therapies in pediatric rheumatology

Author

Guillaume-Czitrom, Séverine, Bachelez, Hervé, Berthelot, Jean-Marie, Bouhnik, Yoram, Bruckert, Eric, Claudepierre, Pascal, Constantin, Arnaud, de Bandt, Michel, Fautrel, Bruno, Gaudin, Philippe, Goëb, Vincent, Gossec, Laure, Gottenberg, Jacques-Eric, Goupille, Philippe, Hachulla, Eric, Huet, Isabelle, Jullien, Denis, Launay, Odile, Lemannf, Marc, Lequerré, Thierry, Maillefert, Jean-Francis, Mariette, Xavier, Marolleau, Jean-Pierre, Martinez, Valérie, Masson, Charles, Morel, Jacques, Mouthon, Luc, Pham, Thao, Pol, Stanislas, Puéchal, Xavier, Richette, Pascal, Saraux, Alain, Schaeverbeke, Thierry, Sellam, Jérémie, Blacher, Jacques, Soubrier, Martin, Sudre, Anne, Viguier, Manuelle, Vittecoq, Olivier, Wendling, Daniel, and Sibilia, Jean

Published
2014
Full Text
View/download PDF

32. Abatacept therapy and safety management

Author

Pham, Thao, Bachelez, Hervé, Berthelot, Jean-Marie, Blacher, Jacques, Claudepierre, Pascal, Constantin, Arnaud, Fautrel, Bruno, Gaujoux-Viala, Cécile, Goëb, Vincent, Gossec, Laure, Goupille, Philippe, Guillaume-Czitrom, Séverine, Hachulla, Eric, Lequerré, Thierry, Marolleau, Jean-Pierre, Martinez, Valérie, Masson, Charles, Mouthon, Luc, Puéchal, Xavier, Richette, Pascal, Saraux, Alain, Schaeverbeke, Thierry, Soubrier, Martin, Viguier, Manuelle, Vittecoq, Olivier, Wendling, Daniel, Mariette, Xavier, and Sibilia, Jean

Published
2012
Full Text
View/download PDF

35. TNF alpha antagonist therapy and safety monitoring

Author

Pham, Thao, Bachelez, Hervé, Berthelot, Jean-Marie, Blacher, Jacques, Bouhnik, Yoram, Claudepierre, Pascal, Constantin, Arnaud, Fautrel, Bruno, Gaudin, Philippe, Goëb, Vincent, Gossec, Laure, Goupille, Philippe, Guillaume-Czitrom, Séverine, Hachulla, Eric, Huet, Isabelle, Jullien, Denis, Launay, Odile, Lemann, Marc, Maillefert, Jean-Francis, Marolleau, Jean-Pierre, Martinez, Valérie, Masson, Charles, Morel, Jacques, Mouthon, Luc, Pol, Stanislas, Puéchal, Xavier, Richette, Pascal, Saraux, Alain, Schaeverbeke, Thierry, Soubrier, Martin, Sudre, Anne, Tran, Tu-Anh, Viguier, Manuelle, Vittecoq, Olivier, Wendling, Daniel, Mariette, Xavier, and Sibilia, Jean

Published
2011
Full Text
View/download PDF

40. Use of a bDMARD or tsDMARD for the management of inflammatory arthritis under checkpoint inhibitors: an observational study.

Author

De La Fuente, Fanny, Belkhir, Rakiba, Henry, Julien, Chi Duc Nguyen, Thao Pham, Germain, Vincent, Gavand, Pierre Edouard, Labadie, Céline, Briere, Claire, Lauret, Ambre, Cardon, Thierry, Mouterde, Gael, Bonnet, Isabelle, Rouxel, Léa, Truchetet, Marie-Elise, Schaeverbeke, Thierry, Richez, Christophe, and Kostine, Marie

Published
2022
Full Text
View/download PDF

43. Use of glucocorticoids in rheumatoid arthritis – Pratical modalities of glucocorticoid therapy: Recommendations for clinical practice based on data from the literature and expert opinion

Author

Dernis, Emmanuelle, Ruyssen-Witrand, Adeline, Mouterde, Gaël, Maillefert, Jean-Francis, Tebib, Jacques, Cantagrel, Alain, Claudepierre, Pascal, Fautrel, Bruno, Gaudin, Philippe, Pham, Thao, Schaeverbeke, Thierry, Wendling, Daniel, Saraux, Alain, and Loët, Xavier Le

Published
2010
Full Text
View/download PDF

44. Tocilizumab: Therapy and safety management

Author

Pham, Thao, Claudepierre, Pascal, Constantin, Arnaud, de Bandt, Michel, Fautrel, Bruno, Gossec, Laure, Gottenberg, Jacques-Eric, Goupille, Philippe, Guillaume, Séverine, Hachulla, Eric, Masson, Charles, Morel, Jacques, Puéchal, Xavier, Saraux, Alain, Schaeverbeke, Thierry, Wendling, Daniel, Bruckert, Eric, Pol, Stanislas, Mariette, Xavier, and Sibilia, Jean

Published
2010
Full Text
View/download PDF

46. Prognosis and follow-up of psoriatic arthritis with peripheral joint involvement: Development of recommendations for clinical practice based on published evidence and expert opinion

Author

Lavie, Frédéric, Salliot, Carine, Dernis, Emmanuelle, Claudepierre, Pascal, Schaeverbeke, Thierry, Tebib, Jacques, Goupille, Philippe, Cantagrel, Alain, Flipo, René-Marc, Gaudin, Philippe, Le Loët, Xavier, Maillefert, Jean-Francis, Paul, Carle, Saraux, Alain, Wendling, Daniel, and Combe, Bernard

Published
2009
Full Text
View/download PDF

47. Pharmacological treatment (biotherapy excluded) of peripheral psoriatic arthritis: Development of recommendations for clinical practice based on data from the literature and experts opinion

Author

Dernis, Emmanuelle, Lavie, Frédéric, Salliot, Carine, Flipo, René-Marc, Saraux, Alain, Maillefert, Jean-Francis, Paul, Carle, Goupille, Philippe, Cantagrel, Alain, Claudepierre, Pascal, Gaudin, Philippe, Tebib, Jacques, Wendling, Daniel, Schaeverbeke, Thierry, Le Loët, Xavier, and Combe, Bernard

Published
2009
Full Text
View/download PDF

49. OX40 Ligand Contributes to Human Lupus Pathogenesis by Promoting T Follicular Helper Response

Author

Jacquemin, Clément, Schmitt, Nathalie, Contin-Bordes, Cécile, Liu, Yang, Narayanan, Priya, Seneschal, Julien, Maurouard, Typhanie, Dougall, David, Davizon, Emily Spence, Dumortier, Hélène, Douchet, Isabelle, Raffray, Loïc, Richez, Christophe, Lazaro, Estibaliz, Duffau, Pierre, Truchetet, Marie-Elise, Khoryati, Liliane, Mercié, Patrick, Couzi, Lionel, Merville, Pierre, Schaeverbeke, Thierry, Viallard, Jean-François, Pellegrin, Jean-Luc, Moreau, Jean-François, Muller, Sylviane, Zurawski, Sandy, Coffman, Robert L., Pascual, Virginia, Ueno, Hideki, and Blanco, Patrick

Published
2015
Full Text
View/download PDF

50. Identification of secreted phosphoprotein 1 gene as a new rheumatoid arthritis susceptibility gene

Author

Gazal, Steven, Sacre, Karim, Allanore, Yannick, Teruel, Maria, Goodall, Alison H, Tohma, Shigeto, Alfredsson, Lars, Okada, Yukinori, Xie, Gang, Constantin, Arnaud, Balsa, Alejandro, Kawasaki, Aya, Nicaise, Pascale, Amos, Christopher, Rodriguez-Rodriguez, Luis, Chiocchia, Gilles, Boileau, Catherine, Zhang, Jinyi, Vittecoq, Olivier, Barnetche, Thomas, Gay, Miguel A Gonzalez, Furukawa, Hiroshi, Cantagrel, Alain, Le Loët, Xavier, Sumida, Takayuki, Hurtado-Nedelec, Margarita, Richez, Christophe, Chollet-Martin, Sylvie, Schaeverbeke, Thierry, Combe, Bernard, Khoryati, Liliane, Coustet, Baptiste, El-Benna, Jammel, Siminovitch, Katherine, Plenge, Robert, Padyukov, Leonid, Martin, Javier, Tsuchiya, Naoyuki, and Dieudé, Philippe

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results